By Dr. Amitha Parvataneni, MD | ASM.D. Aesthetics, Troy, Michigan
TL;DR
- Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) are both weekly injections that reduce hunger by mimicking natural gut hormones that signal fullness.
- Tirzepatide targets two hormonal pathways (GLP-1 and GIP) instead of one, and clinical trials consistently show it produces greater weight loss.
- Neither medication is a quick fix. Both work best with physician oversight, regular lab monitoring, and realistic expectations about timeline and maintenance.
- The right choice depends on your individual health history, prior medication experience, and goals — there is no one-size-fits-all answer.
- If you are in the metro Detroit area, I am happy to walk through your options in person at ASM.D. Aesthetics in Troy.
In This Article
- Why weight loss medications are changing the game
- How GLP-1 and GIP receptors work, explained simply
- Semaglutide: what it is, how it works, who it's best for
- Tirzepatide: what it is, how it works, why it's often stronger
- Head-to-head comparison: results, side effects, cost, dosing
- How I determine which medication is right for each patient
- What physician supervision actually means
- Realistic expectations: timeline, maintenance, and your life
- Frequently Asked Questions
Why Weight Loss Medications Are Changing the Game
If you've spent years doing everything right — eating carefully, exercising consistently — and still can't move the number on the scale, I want you to know something first: that is not a failure of willpower.
Weight is far more complicated than calories in and calories out. Your hormones, your metabolism, your genetics, and even the bacteria in your gut all play a role in how your body stores and releases fat. For many people, diet and exercise alone can only do so much against that biology.
That's what makes the current generation of weight loss medications genuinely different from anything we've had before. Semaglutide and tirzepatide don't work by suppressing your appetite through stimulants or blocking fat absorption. They work by changing the hormonal signals that drive hunger and fullness in the first place. The result, in many patients, is a level of weight loss that simply wasn't achievable before without surgery.
I've been watching this space closely, and I want to give you the clearest, most honest picture I can — so you can decide what's right for you.
How GLP-1 and GIP Receptors Work, In Plain Language
You don't need to know the biochemistry. But a quick, plain-language explanation of how these medications work makes everything else easier to understand.
The hunger signal problem
Your body has several hormones that regulate hunger and blood sugar. Two of the most important are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Think of these as the "I've had enough" messengers your gut sends to your brain after you eat.
In many people who struggle with weight, these signals are quieter than they should be. The brain doesn't get a strong enough "full" signal, so hunger persists even when the body has enough fuel.
What these medications do
Both semaglutide and tirzepatide mimic these natural hormones. They bind to the same receptors your body uses, essentially turning up the volume on the fullness signal. The practical effects are significant:
- You feel full sooner and stay full longer.
- Cravings — particularly for high-calorie foods — diminish noticeably.
- Your stomach empties more slowly, which also reduces blood sugar spikes after meals.
- Your liver produces less glucose.
The result is that many people eat less naturally, without the constant mental effort of trying to resist hunger.
Semaglutide: What It Is, How It Works, and Who It's Best For
Semaglutide targets one receptor: GLP-1. It was originally developed as a treatment for type 2 diabetes (brand name Ozempic) and later approved specifically for weight management at a higher dose (brand name Wegovy).
The clinical results
In the STEP 1 trial — one of the landmark studies on semaglutide for weight loss — participants lost an average of about 15% of their body weight over 68 weeks. For someone who starts at 220 pounds, that's roughly 33 pounds. That was a meaningful leap beyond anything previously available without surgery.
Who tends to respond well
Semaglutide is a strong starting point for many patients. It's particularly well-studied, has been on the market longer, and has a well-understood side effect profile. Patients who have had good experiences with GLP-1 medications in the past tend to do well with it.
What to expect
Semaglutide is a once-weekly injection given under the skin, typically in the abdomen, thigh, or upper arm. The dose starts low and increases gradually over several months. The slow titration helps your body adjust and reduces the likelihood of nausea.
Tirzepatide: What It Is, How It Works, and Why It's Often Stronger
Tirzepatide is newer. It targets both GLP-1 and GIP receptors — two pathways instead of one. That dual action is what sets it apart, and it's why clinical results have been consistently more impressive.
Brand names: Mounjaro (prescribed for type 2 diabetes) and Zepbound (prescribed for weight management). Same drug, different FDA indications.
The clinical results
In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide lost an average of 22.5% of their body weight over 72 weeks. At 220 pounds, that's approximately 50 pounds. This is the kind of result that, historically, was only seen with bariatric surgery.
More recently, a direct head-to-head trial called SURMOUNT-5 compared tirzepatide to semaglutide directly. Tirzepatide produced roughly 20% weight loss versus 14% for semaglutide — a meaningful and statistically significant difference.
Why the dual mechanism matters
The GIP receptor does something interesting: it appears to affect how fat tissue responds to insulin and may reduce the inflammatory signals that make weight loss harder. Adding GIP action on top of GLP-1 seems to amplify the appetite-suppressing effects in a way that's greater than either alone.
Who tends to respond well
Tirzepatide is often the first consideration for patients who want the strongest available results and tolerate the medication well. It's also a strong option for patients who have tried semaglutide and want to see whether a different mechanism produces better outcomes for their body.
Head-to-Head Comparison: Results, Side Effects, Cost, and Dosing
Here's the direct comparison, as clearly as I can make it.
Weight loss results
| Medication | Clinical Trial | Avg. Weight Loss |
|---|---|---|
| Semaglutide (Wegovy) | STEP 1 | ~15% |
| Tirzepatide (Zepbound) | SURMOUNT-1 | ~22.5% |
| Head-to-Head (SURMOUNT-5) | SURMOUNT-5 | 20% vs. 14% |
Tirzepatide produces greater average weight loss. That said, individual response varies. Some patients do exceptionally well on semaglutide, and not everyone reaches the trial averages.
Side effect profiles
Both medications share a similar side effect profile because they work on overlapping pathways. The most common effects are:
- Nausea, particularly in the first few weeks after a dose increase
- Vomiting (less common)
- Diarrhea or constipation
- Reduced appetite (this is the desired effect, but it can feel unfamiliar)
Most side effects are temporary and improve as your body adjusts. The slow dose escalation protocol exists specifically to minimize this.
Rare but serious risks exist with both medications, including a potential association with thyroid tumors seen in animal studies. This is why a thorough medical history review matters before starting either medication.
Dosing schedule
Both are once-weekly subcutaneous injections. Tirzepatide starts at 2.5mg per week and can escalate to 15mg. Semaglutide (Wegovy) starts at 0.25mg and escalates to 2.4mg. The titration schedules differ slightly but both are designed around slow, gradual increases.
Cost
Both medications are expensive without insurance. List prices as of early 2026 are roughly $900–$1,400 per month depending on dose and pharmacy. Coverage has been expanding, particularly for the diabetes-indicated versions, but weight management coverage varies significantly by plan.
How I Determine Which Medication Is Right for Each Patient
This is where the individual conversation matters most.
When I sit down with a new patient for a medical weight loss consultation, I'm not running through a checklist. I'm trying to understand your full picture: your weight history, what you've tried before, your current health conditions, your medications, your goals, and what you're realistically willing to commit to.
Your starting point. If you have a significant amount of weight to lose and no contraindications to tirzepatide, the superior efficacy data makes it a strong candidate. If you're closer to your goal weight or have concerns about stronger effects, semaglutide may be the right starting point.
Your health history. Certain conditions affect which medication is safer or more appropriate. A personal or family history of thyroid cancer, pancreatitis, or certain gastrointestinal conditions requires careful discussion before starting either medication.
Your prior experience. If you've tried a GLP-1 medication before, what happened? Did you tolerate it well? Did you plateau? That history tells me a lot about how to approach your next step.
Your lifestyle. These medications work best alongside real attention to nutrition and movement. I want to understand what your daily life actually looks like — not what you wish it looked like. That way, the plan we build together is one you can actually follow.
What Physician Supervision Actually Means
I want to be direct about this, because I know there are online pharmacies offering these medications with minimal or no medical oversight. I understand the appeal. But I'd be doing you a disservice if I didn't tell you what you're giving up.
Baseline labs before you start. Thyroid function, kidney function, liver enzymes, fasting glucose, HbA1c, and a lipid panel at minimum. These establish your starting point and screen for contraindications.
Monitoring as you progress. Labs are repeated at regular intervals. We track not just your weight but your metabolic health — because the goal is a healthier body, not just a smaller number on the scale.
Dose adjustments based on your response. The titration schedules in clinical trials are starting points, not rigid rules. Some patients move more slowly. Some tolerate higher doses well and benefit from faster escalation. This is a conversation, not a protocol.
Management of side effects. Nausea, fatigue, and constipation are manageable with the right guidance. Without a physician, you're often left googling symptoms and hoping for the best.
A plan for long-term maintenance. What happens when you reach your goal? That's a question a prescribing physician should be asking from day one.
Realistic Expectations: Timeline, Maintenance, and Your Life
I want to give you an honest picture, because unrealistic expectations are one of the most common reasons people feel let down even when a medication is actually working.
What the timeline typically looks like
Most patients begin to notice reduced appetite within the first two to four weeks. Meaningful weight loss — the kind that shows up on the scale and in how your clothes fit — typically becomes apparent around weeks six to ten. The most significant progress often happens between months three and nine.
That said, this is not a straight line. Weight loss is non-linear. There will be weeks where the scale doesn't move, and that doesn't mean the medication has stopped working.
This is not a temporary fix
Here is something I tell every patient directly: these medications work as long as you take them. When you stop, hunger signals return to baseline for most people, and weight can return with them. That's not a failure of the medication — that's just biology. It's the same reason someone with high blood pressure needs to keep taking their medication.
This means we need to think about a long-term plan. Some patients stay on a maintenance dose indefinitely. Others use a period of medication-assisted weight loss to build new habits and then taper carefully with close monitoring.
What you bring to this
A medication can make you feel less hungry. It cannot make you choose nourishing food, move your body, manage stress, or sleep enough. The patients who do best treat the medication as a powerful tool — not a substitute for lifestyle but a leveler of the playing field that makes lifestyle changes far more achievable than they were before.
Frequently Asked Questions
Is tirzepatide or semaglutide covered by insurance in Michigan? Coverage varies significantly by plan and diagnosis. Both medications are more commonly covered when prescribed for type 2 diabetes (Mounjaro and Ozempic) than for weight loss alone (Zepbound and Wegovy). As of 2026, some Michigan commercial plans and Medicaid programs have expanded coverage for obesity treatment. We review your insurance situation at your consultation and help you understand your options, including manufacturer savings programs that can reduce out-of-pocket costs substantially.
Can I get a GLP-1 medication if I don't have diabetes? Yes. Wegovy (semaglutide) and Zepbound (tirzepatide) are both FDA-approved specifically for chronic weight management in adults with obesity, or overweight with at least one weight-related health condition. You do not need a diabetes diagnosis to qualify. What matters is your BMI, your health history, and whether physician-supervised weight loss is appropriate for you.
What happens if I plateau on my weight loss medication? Plateaus are a normal part of the process and almost always have a solution. Common causes include needing a dose adjustment, a change in lifestyle factors, or occasionally a switch to a different medication. Under physician supervision, we have real tools to work with. We catch plateaus early and respond to them, rather than waiting and hoping.
What is the difference between Mounjaro and Zepbound? They contain the same active ingredient: tirzepatide. Mounjaro is the brand name used for the type 2 diabetes indication. Zepbound is the brand name used for weight management. The drug itself is identical. The difference is the FDA approval and how your insurance classifies the prescription, which can affect coverage significantly.
The Bottom Line
If you've been researching tirzepatide versus semaglutide and feeling overwhelmed by the conflicting information online, I hope this has given you some clarity.
Both medications represent a real shift in what's possible for medical weight loss. Tirzepatide tends to produce greater results for most patients. Semaglutide is well-established, effective, and the right choice for many people. Which one is right for you depends on your individual health picture — that's a conversation worth having in person.
At ASM.D. Aesthetics in Troy, Michigan, medical weight loss is physician-led from the first consultation through long-term maintenance. We review your labs, discuss your history, explain your options honestly, and build a plan that's actually built around you.
Schedule a medical weight loss consultation at ASM.D. Aesthetics in Troy, MI.
Call or text: (313) 949-0418
Schedule a consultation with ASM.D. Aesthetics
Research & Sources
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine, 2021.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022.
- Wadden TA, et al. "SURMOUNT-5: Tirzepatide vs. Semaglutide for Chronic Weight Management." New England Journal of Medicine, 2025.
- U.S. Food and Drug Administration. "FDA Approves New Medication for Chronic Weight Management." FDA.gov, 2021.
- U.S. Food and Drug Administration. "FDA Approves Novel, Dual-Targeted Treatment for Chronic Weight Management." FDA.gov, 2023.
- Nauck MA, D'Alessio DA. "Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes." Cardiovascular Diabetology, 2022.
- American Board of Obesity Medicine. "Obesity as a Disease." ABOM.org.
All sources are peer-reviewed publications from NEJM, FDA.gov, or recognized clinical obesity medicine organizations.